Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers Squibb has demonstrated a significant increase in positivity with a rise in the probability of success (PoS) for key products, specifically milvexian and iber/mezi, leading to projected risk-adjusted sales of $1.2 billion and $3.6 billion, respectively, by 2033. The company has received favorable guidance that exceeds market consensus, fostering investor confidence and attracting attention from multiple experts in the multiple myeloma space, indicating a promising market for its drug offerings. Furthermore, Bristol-Myers Squibb's financial stability is underscored by its solid portfolio performance, prudent cost management, and consistent dividend distribution of approximately $2.50, contributing to a positive long-term outlook.

Bristol-Myers Squibb faces potential revenue and earnings setbacks due to significant delays in regulatory approval and product launches. The company's forward EV/EBITDA multiple, which remains below the peer average of 11.2x, highlights a market perception of elevated risk associated with its growth prospects. Additionally, ongoing risks in clinical trials, such as the possibility of denied approvals and competition, could hinder the firm's ability to maintain its market position in the immuno-oncology sector.